Chris Katje
Research analyst, growth, value, IPOs

Put A Royalty Legend In Your Portfolio With Ligand Pharmaceuticals

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) are up 135% in 2013. Despite this historic rise, the royalty collecting pharmaceutical company has plenty of room to run as it sees more drug approvals and returns cash to shareholders.

Company

From the company's website:

"Ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. We operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders."

New Approval With Pfizer for Menopause

Earlier in the week, Ligand Pharmaceuticals saw a drug it shares with Pfizer (NYSE:PFE) approved...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details